What is DalCor Pharmaceuticals?
DalCor Pharmaceuticals is a biopharmaceutical firm focused on precision medicine for cardiovascular diseases. Their lead candidate, dalcetrapib, is a pharmacogenetic treatment designed to mitigate the risk of recurrent myocardial infarction in patients with a specific genetic profile (AA genotype at the rs1967309 location in the ADCY9 gene). The company is currently advancing dalcetrapib through the Dal-GenE-2 Phase 3 clinical trial, building on positive outcomes from the dal-GenE trial. DalCor's therapeutic focus targets individuals with cardiovascular conditions, including those affected by obesity, diabetes, and hypertension, positioning them within a critical segment of the healthcare market.
How much funding has DalCor Pharmaceuticals raised?
DalCor Pharmaceuticals has raised a total of $230M across 3 funding rounds:
Series A
$50M
Series B
$100M
Series D
$80M
Series A (2015): $50M with participation from Caisse de du00e9pu00f4t et placement du Quu00e9bec, CTI Life Sciences, Sanderling Ventures, and Fonds de solidaritu00e9 FTQ
Series B (2016): $100M led by Caisse de du00e9pu00f4t et placement du Quu00e9bec, Fonds de solidaritu00e9 FTQ, CTI Life Sciences, and Sanderling Ventures
Series D (2023): $80M supported by Fonds de Developpement Économique and TB Alliance
Key Investors in DalCor Pharmaceuticals
Caisse de dépt et placement du Québec
Caisse de dépt et placement du Québec is a full-service portfolio investment company managing institutional funds, primarily from public and private pension and insurance funds in Quebec. Founded in 1965, it is headquartered in Montreal.
CTI Life Sciences
CTI Life Sciences Fund is a Canadian venture capital firm specializing in catalyzing innovative biotech ideas into scalable companies. With a focus on various therapeutic modalities, they aim for long-term value creation and expedited exits.
Sanderling Ventures
Sanderling Ventures is an investment firm founded in 1979 that specializes in building new biomedical companies through early-stage financing and active management. Their investment areas span therapeutics, drug delivery, and medical devices.
What's next for DalCor Pharmaceuticals?
The recent major strategic investment in DalCor Pharmaceuticals signals a pivotal stage for the company, likely enabling the acceleration of its Phase 3 clinical trials and the expansion of its research and development pipeline. This capital infusion is expected to support the final stages of dalcetrapib's clinical evaluation and prepare for potential regulatory submissions. The company's commitment to precision medicine in cardiovascular health, particularly for high-risk patient populations, suggests a strategic focus on developing targeted therapies that address unmet medical needs. Future growth will likely involve navigating complex regulatory pathways and establishing commercialization strategies for its innovative treatments.
See full DalCor Pharmaceuticals company page
